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Abstract 
Dendritic cells are the most potent antigen-presenting cells, but their roles in blood-stage 
malaria-infection are not fully understood.  We examined the effects of Flt3 ligand, a 
cytokine which induces dendritic cell production, in vivo on the course of infection with 
Plasmodium berghei ANKA.  Mice treated with Flt3 ligand showed preferential 
expansion of CD8+ dendritic cells and granulocytes, lower parasitemia, and were 
protected from the development of lethal experimental cerebral malaria (ECM).  Rag2 
knock-out mice treated with Flt3 ligand also showed inhibition of parasitemia, suggesting 
that this protection was, at least in part, due to stimulation of innate immunity.  However, 
it was unlikely that the inhibition of ECM was simply due to the reduction in parasitemia.  
In the peripheral T cell compartment, CD8+ T cells were markedly increased in Flt3 
ligand-treated mice after infection.  These CD8+ T cells expressed CD11c and 
upregulated CXCR3, while the expression of CD137, CD25 and granzyme B was 
reduced.  In the brain, the number of sequestered CD8+ T cells was not significantly 
different between treated and untreated mice, while the proportion of CD8+ T cells that 
produce IFN- and granzyme B was significantly reduced in treated mice.  In addition, 
sequestration of parasitzed RBCs in the brain was reduced, suggesting that altered CD8+ 
T cell activation and reduced sequestration of parasitized RBCs culminated in inhibition 
of ECM development.  These results suggest that the quantitative and qualitative change 
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Introduction 
Malaria is one of the most serious infections in the world, and is responsible for more than 
one million deaths each year.  Infection with Plasmodium falciparum induces a wide 
range of severe pathologies including cerebral malaria (CM), one of the major causes of 
mortality of this important parasite (14, 29, 36).  Infection with Plasmodium berghei 
ANKA (PbA), a rodent malaria parasite, induces neurological symptoms and death in 
C57BL/6 and CBA mice, and is widely used as a mouse model of experimental cerebral 
malaria (ECM) (8).  Previous studies using the PbA-infection model indicate the 
importance of brain-sequestered CD8+ T cells in the pathogenesis of ECM. Depletion of 
CD8+ T cells in C57BL/6 mice prevented development of ECM, while reconstitution of 
CD8+ T cells in RAG deficient mice, which lack both T and B cells, resulted in the 
development of ECM after infection with PbA (3, 26).  In addition, concomitant 
accumulation of parasitized RBCs in the brain is critical for the development of ECM (1). 
Recruitment of CD8+ T cells to the brain and the pathogenesis of ECM is dependent on 
chemokine receptor CCR5 (2, 26), and CXCR3 expressed on CD8+ T cells, as well as 
CXCR3 ligands CXCL9/CXCL10 (6, 24, 37).  In the effector phase, production of 
proinflamatory cytokines such as IFN- and cytotoxic activity of CD8+ T cells play 
critical roles in the pathogenesis of ECM (26, 40).   
 
CD11c+ dendritic cells (DCs) are professional antigen-presenting cells that can prime 
naïve T cells leading to the development of effector T cells.  DCs can phagocytose 
malaria parasitized red blood cells (pRBC) during infection and can present malaria 
antigen in both MHC class I and class II pathways, activating malaria-specific CD8+ and 
CD4+ T cells, respectively, thus playing critical roles in the induction of protective 
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immunity against Plasmodium infection (15, 17, 19, 20, 25, 33).  However, DCs also play 
an important role in the pathogenesis of ECM, a T cell-dependent disease.  It was 
previously shown that depletion of conventional DCs, but not plasmacytoid DCs, resulted 
in reduced activation of malaria-specific T cells and inhibition of ECM development (10).  
The regulatory function of DCs in the pathogenesis of CM, however, is not completely 
understood.   
 
Flt3 ligand (Flt3L) is an important cytokine for the differentiation and homeostasis of 
DCs (32). DCs differentiate from flt3+ progenitor cells at a steady state (16). 
Administration of Flt3L induces a drastic increase of DCs in spleen and lymph nodes (21).  
In contrast, the lack of Flt3L leads to severe reductions in DC numbers in many tissues 
(22).  It was previously shown that the number and phenotype of DCs in the spleen 
fluctuated during infection with malaria parasite (33, 39).  However, it was unclear what 
effect this fluctuation of DC numbers had on the priming of malaria-specific T cells and 
the pathogenesis of ECM. In this study, we stimulated the expansion of DCs in vivo by 
administration of Flt3L prior to infection with PbA, and examined its effects on the 
activation of the immune system as well as the development of ECM.  The results showed 
that Flt3L-treated mice were protected from ECM and exhibited altered T cell activation 
phenotypes. These studies suggest an important regulatory function for DCs in the 
activation of T cells as well as the pathogenesis of ECM.   
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Materials and Methods 
Mice and plasmid transduction 
Rag-2-/- mice of C57BL/6 background (31) were provided by Dr. Y. Yoshikai (Kyushu 
University, Fukuoka, Japan), and were maintained in the Laboratory Animal Center for 
Animal Research at Nagasaki University.  C57BL/6 mice were purchased from SLC 
(Hamamatsu, Japan).  The animal experiments reported herein were conducted according 
to the Guidelines of the Laboratory Animal Center for Biomedical Research at Nagasaki 
University.  
The coding sequence for the extracellular domain (amino acids from 1 to 189) of mouse 
Flt3L was obtained by PCR from cDNA prepared from mouse spleen using primer pairs 
5’-GATCCACCATGACAGTGCTGGCGCCAGC-3’ and 
5’-GATCTACTGCCTGGGCCGAGGCTCTG-3’.  After confirming the sequence, the 
PCR product was cloned into pCAGGS, resulting in pCAGGS-Flt3L. The plasmid was 
purified using PureYieldTM Plasmid Maxiprep System (Promega, Madison, WI), and its 
endotoxin level was 2.43 EU (equivalent to 0.55ng endotoxin) per g DNA as determined 
by Limulus test (Wako, Osaka, Japan). A solution containing the plasmid (5g in PBS) 
was injected into mice using the hydrodynamics method, as previously described (12). 
 
GFP-expressing parasites and PbA infection 
PbA was originally obtained from Dr. R.E. Sinden (Imperial College London, London, 
UK).  Recombinant PbA parasites that constitutively express GFP (PbA-GFP) were 
engineered as previously described (25).  The gene construct based on pBluescript KS(+) 
(Stratagene) contains a PbA dihydrofolate reductase-thymidyltransferase-ts (DHFR-ts) 
gene, PbA hsp70 5’ untranslated region, its N-terminal coding sequence and coding 
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sequence of GFP.  PbA merozoites were transfected with the DNA construct by 
electroporation and were selected in rats using pyrimethamine. Surviving parasites were 
cloned by limiting dilution in mice. 
PbA was maintained by passing through BALB/c mice.  For infection, mice were 
inoculated with parasitized RBC (pRBC) (1x106) i.p. unless the dose was specifically 
indicated. Parasitemia of infected mice was monitored by microscopic examination of 
Giemsa stained tail blood smears. Typically, five to six days after infection with PbA, 
mice began to show neurological signs, such as hunching, paralysis, ataxia, and 
succumbed to death within ten days of infection (6). PBS solution containing 2% Evans 
blue dye was injected into mice on day 6 after PbA infection. After one hour mice were 




To prepare DCs, spleens were cut into small fragments, incubated with RPMI1640 
containing collagenase (100U/ml), mechanically disrupted and filtered to prepare 
single-cell suspensions.  After lysis of RBC, cells were stained with FITC-anti-CD4, 
APC-anti-CD8, FITC-anti-MHC class II, FITC-anti-CD40, FITC-anti-CD80, 
FITC-anti-CD86, PE-anti-CD11c, PECy7-anti-CD3, PECy7-anti-CD19, 
PECy7-anti-NK1.1, PECy7-anti-Ter119, FITC-anti-TCR, FITC-anti-F4/80, 
PE-anti-Gr1, APC-anti-Ly6G, APC-anti-CD45, APCCy7-anti-Ly6C, 
APCCy7-anti-CD45, biotin-anti-DX5, biotin-anti-CD11c, biotin-anti-CD11b Abs and 
PECy7- or APC-streptavidin.  Antibodies were purchased from BD Bioscience (San Jose, 
CA), eBioscience (San Diego, CA) or Biolegend (San Diego, CA).  For intracellular 
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staining of IFN- and granzyme B, splenocytes or brain-sequestered leukocytes were 
cultured on plates coated with anti-TCR mAb (H57; 2g/ml) for 5 hrs with an addition of 
Golgi stop (BD Biosciences) during the final 4 hs.  The cells were collected and stained 
with anti-IFN- or anti-granzyme B mAb according to the manufacturer’s instruction.  
For intracellular staining of Foxp3, splenocytes were stained using anti-Foxp3 staining 
set (eBioscience) according manufacturer’s instruction. Cells were analyzed using 
FACSCanto II (BD Bioscience) and data analysis was performed using CellQuest 
software.  The following cell populations were defined; DCs, 
CD11chighCD3-CD19-DX5-; NK cells, NK1.1+ TCR-; macrophages, 
F4/80highCD11blowCD11c-; granulocytes, Gr1highLy6G+CD11b+. 
 
Cytokine quantification 
Serum levels of IFN- and Flt3L were quantified using a cytometric bead array (CBA) 
assay (BD Bioscience) and mouse Flt3 ligand Quantikine ELISA kit (R&D systems, 
Minneapolis, MN), respectively.  Splenic CD4+ and CD8+ T cells were purified using 
anti-CD4 or anti-CD8 IMag (BD Biosciences), respectively.  Splenic DCs were purified 
using anti-CD11c MACS microbeads and autoMACS (Miltenyi Biotech, Gladbach, 
Germany) or by cell sorting of CD11c+/MHC class II+ cells using FACSAria (BD 
Bioscences)(Fig. 1D). CD4+ or CD8+ T cells (1x105 cells/well) were cultured for 48 hr on 
96-well plates coated with anti-TCR mAb (H57, 2 g/ml) or with DCs (3x104 cells/well) 
pulsed with RBC lysate (1mg/ml) for two hours.  The levels of IFN-in the supernatant 
were determined by ELISA as described (25). 
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Preparation of brain-sequestered leukocytes and RBCs 
Mice were sacrificed 6 days after PbA-infection, and brain-sequestered leukocytes were 
prepared as previously described with slight modification (24).  Briefly, euthanized mice 
were perfused intracardially with PBS, and brains were removed.  Brains were crushed 
and treated with collagenase (100U/ml) at 37℃ for 15 min. The brain extract was 
centrifuged at 1,500 rpm for 20 min in 30% Percoll solution to remove debris and the cell 
pellet was collected.  Cells were treated with Gey’s solution to remove RBC, stained with 
antibodies and analyzed by flow cytometry.  After gating for CD45+Ter119- cells, CD4+ 
and CD8+ T cells were defined as TCR+CD4+ and TCR+CD8+ cells, respectively.  For 
analysis of pRBCs, total numbers of RBCs were counted after Percoll centrifugation of 
brain extract without RBC lysis.  Cells were stained with PECy7-anti-Ter119 and 
APC-anti-CD45 mAbs and were analyzed using FACSCanto II.  The proportion of pRBC 
was determined by microscopic examination in a manner similar to standard blood films. 
The number of pRBC in brains was calculated by multiplying the number of RBCs with 
the proportion of pRBC. 
 
Depletion of neutrophils 
The hybridoma cell line secreting RB6-8C5 mAb (anti-Gr1) was provided by Dr. H. Asao 
(Yamagata University, Yamagata, Japan) (7).  Cells were cultured using CELLine system 
(BD Biosciences) and the supernatant was purified using a HiTrap protein G HP column 
(GE healthcare).  To deplete neutrophils, mice received i.p. injection of mAb (50 g) two 
days before the infection.  Anti-Gr1 mAb RB6-8C5 is specific for both Ly6C and Ly6G 
(11).  Since Ly6C is expressed on some T cells, we used 50 g mAb, that depleted >99% 
Ly6G+ granulocytes, while maintaining the majority of T cells (>85%) two days after the 
     9 
treatment.  Under the conditions used, we estimated that the effect on the Ly6C+ 
population was minimal. 
 
Statistics 
Results are expressed as means ± SD. Statistical analysis was performed using 
Mann-Whitney test between two experiment groups or the logrank test for survival, and 
the data were calculated using GraphPad Prism software (version 4.0).  Differences with 
P<0.05 were considered significant. 
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Results 
 
Prevention of cerebral malaria by Flt3L-treatment 
We introduced a plasmid encoding mouse Flt3L into C57BL/6 mice using the 
hydrodynamics method to stimulate expansion of DCs in vivo. The serum concentration 
of Flt3L was significantly increased one week after Flt3L-treatment (Fig. 1A).  The 
numbers of DCs and granulocytes in the spleen of treated mice were significantly 
increased as previously reported (38), while numbers of NK cells and macrophages were 
not increased (Fig. 1B).  The number of RBCs in peripheral blood was also unchanged, 
consistent with the previous report that megakaryocyte/erythrocyte progenitors in the 
bone marrow do not express Flt3 and do not expand after Flt3L administration (16).  We 
next examined DC sub-populations and their expression of MHC and co-stimulatory 
molecules (Fig. 1C).   The proportion of CD8+ DCs was increased while that of CD4+ 
DCs was reduced in the spleen of Flt3L-treated mice when compared with those of 
untreated mice.  The expression levels of MHC class II, CD80 and CD86 were not 
significantly different from those of untreated mice, while that of CD40 was slightly 
increased.  The ability of these DCs to present malaria antigen was evaluated in vitro (Fig. 
1D). DCs from Flt3L-treated mice stimulated IFN- production of malaria-specific CD8+ 
T cells much better than control DCs, which is consistent with the increase in the 
proportion of CD8+ DCs in Flt3L-treated mice (9, 19). 
 
To determine the effect of Flt3L on the pathogenesis of PbA-infection, Flt3L-treated and 
untreated mice were infected with PbA, and their survival was monitored (Fig. 2A).  Most 
PbA-infected control mice died within 8 days with severe symptoms of ECM such as 
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coma.  In contrast, Flt3L-treated mice were clearly protected from lethal CM. Mild 
symptoms of ECM such as fur ruffling or hunching were observed in some of the 
Flt3L-treated mice within ten days, but none succumbed to death during this period.  The 
level of parasitemia was significantly reduced in Flt3L-treated mice 5 days after infection 
with PbA, but continued to increase to more than 50% within 2 weeks of the infection.  
The few control mice that survived the critical period of ECM also showed a similar 
increase in parasitemia.  We tested various doses of the Flt3L-plasmid and found an 
inverse correlation between the number of DCs in the spleen and the levels of parasitemia 
5 days after infection (Supplemental Fig. 1).  In addition, mice that were transfered with 
Flt3L-induced DCs showed reduced parasitemia levels, suggesting that these DCs were 
directly involved in anti-malaria effects of Flt3L-treatment during early period of the 
infection (Supplementary Fig. 2).  To visualize the integrity of the blood brain barrier in 
infected mice, the leakage of dye in the brain was examined after i.v. injection of Evans 
blue (Fig. 2B). In control mice, brains were stained with the dye, suggesting the blood 
brain barrier was impaired. However, the brains of Flt3L-treated mice showed little 
leakage, indicating that the integrity of blood brain barrier was maintained. These results 
suggest that Flt3L-treatment effectively prevented the development of ECM. 
 
Since parasitemia levels were inhibited during the early period of the infection in 
Flt3L-treated mice, we suspected that innate immune responses might be responsible for 
controlling the parasitemia.  To examine this possibility, Rag2-/- mice, which lack both T 
and B cells, were treated with Flt3L and were infected with PbA (Fig. 2C).  The levels of 
parasitemia in Flt3L-treated Rag2-/- mice were lower than parasitemia levels in untreated 
mice during the early period of the infection, suggesting that enhancement of innate 
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immunity by Flt3L-treatment effectively limited the expansion of PbA during this period.  
However, this effect was transient and was not sufficient for protection as the parasitemia 
levels continued to rise in infected Rag2-/- mice. Since DCs can phagocytose 
Plasmodium-infected RBC (15), we examined the possibility that Flt3L-expanded DCs 
phagocytosed pRBC.  Flt3L-treated and untreated wild-type C57BL/6 mice were infected 
with PbA-GFP, and splenocytes were examined 5 days later using flow cytometry (Fig. 
2D). In both Flt3L-treated and untreated mice an equivalent proportion of DCs 
phagocytosed PbA-GFP.  In addition to DCs, phagocytosis of PbA-GFP was mediated by 
a population of CD11c-Ly6C+ cells, which are similar to recently described inflammatory 
monocytes (34). 
 
It is possible that the inhibition of ECM-development in Flt3L-treated mice was due to 
the reduction in parasitemia levels during a critical window for the disease, the early 
period of infection. To closely examine the relationship between ECM development and 
parasitemia levels during the early infection period, mice were infected with lower doses 
of pRBC (Fig. 2E).  Although mice infected with 1.5x 105 pRBC showed parasitemia 
levels similar to Flt3L-treated mice infected with 1 x 106 pRBC, the untreated mice 
infected with the lower pRBC dose did develop lethal CM.  Since IFN- plays a critical 
role in the pathogenesis of ECM (40), we determined serum levels of IFN- in 
Flt3L-treated and untreated mice during infection (Fig. 2F).  The level of IFN- was 
slightly increased in Flt3L-treated mice when compared with untreated mice after PbA 
infection.  To exclude the possibility that Flt3L directly inhibited parasite growth, we 
examined the effect of Flt3L on the growth of PbA in vivo prior to the expansion of DCs.  
Thus, we treated mice with Flt3L 4 days after the infection (Fig. 2G).   Two days after 
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Flt3L-treatment, when serum Flt3L levels significantly increased (1.71+ 0.79 ng/ml in 
treated vs. 0.32 + 0.02 ng/ml in untreated mice), the parasitemia level was not reduced, 
suggesting that Flt3L did not directly inhibit parasite growth.  Collectively, we concluded 
that it was unlikely that inhibition of ECM development in Flt3L-treated mice was simply 
due to the inhibition of parasitemia or due to the change in systemic IFN- response. 
 
Expansion and activation of CD8+ T cells in Flt3L-treated PbA-infected mice.   
Since ECM is a T cell-dependent disease, we next examined the number and phenotype of 
T cells 5 days after infection with PbA. The number of CD4+ and CD8+ T cells did not 
change significantly after PbA infection in untreated mice, but increased dramatically in 
both spleen and peripheral blood after PbA infection in Flt3L-treated mice (Fig. 3A).  In 
particular, the increase in CD8+ T cells was prominent.  To investigate the function of 
these CD8+ T cells, they were stimulated with DC pulsed with pRBC lysate.  CD8+ Ｔ 
cells from Flt3L-treated mice produced IFN- in response to malaria antigen at levels 
similar to or higher than those from untreated mice, suggesting that the priming and IFN- 
production of CD8+ T cells specific for malaria antigen was not impaired in Flt3L-treated 
mice. (Fig. 3B).  
 
We next examined the phenotypes of CD8+ T cells, since they are critical for the 
pathogenesis of ECM.  Interestingly, a large population of CD8+ T cells was found to 
express CD11c in mice infected with PbA, while CD11c was not significantly induced in 
CD4+ T cells upon PbA infection (Fig. 4A). The majority of CD11c+CD8+ T cells 
co-expressed CD44, suggesting that they were recently activated effector T cells (Fig. 
4B). CD11c is a well-known marker of DCs, but it was previously reported that some 
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activated CD8+ T cells express CD11c (4, 13, 18). We sorted CD11c+CD8+ and 
CD11c-CD8+ T cells from the spleen of PbA-infected mice, and stimulated them with 
anti-TCR mAb in vitro.  CD11c+CD8+ T cells produced IFN- at a level much higher than 
CD11c-CD8+ T cells, confirming that they were primed T cells (data not shown).  
Focusing on CD11c+CD8+ T cells we examined their expression of other 
activation-associated molecules and chemokine receptor, CXCR3, which was previously 
reported to be instrumental to ECM-pathogenesis (Fig. 4B, C) (6, 24, 37). The expression 
of CD44 and CXCR3 on CD11c+CD8+ T cells was similarly up-regulated in both 
Flt3L-treated and untreated mice.  However, the expression of CD25, CD137 and 
granzyme B in CD11c+CD8+ T cells from Flt3L-treated mice was lower than their 
expression in CD11c+CD8+ T cells from untreated mice (Fig. 4C).  These results suggest 
that the activation status of CD8+ T cells in Flt3L-treated mice was distinct from that in 
untreated mice during infection with PbA.   
 
Next, cells sequestered in the brain of PbA-infected mice 6 days after infection with PbA 
were examined (Fig. 4D).  The number of both CD8+ and CD4+ T cells dramatically 
increased in both Flt3L-treated and untreated mice after PbA infection.  No significant 
difference in the number of brain-sequestered T cells between Flt3L-treated and untreated 
mice was found.  The majority of brain-sequestered CD8+ T cells expressed CD44 and 
CD11c indicating that they were activated T cells.  The level of CD44 expression was 
similar in both Flt3L-treated and untreated mice, while CD11c expression levels were 
slightly lower in brain-sequestered CD8+ T cells from Flt3L-treated mice when compared 
with those from untreated mice.  To gain insight on the function of these 
brain-sequestered CD8+ T cells, expression of IFN- and granzyme B was evaluated by 
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intracellular staining after stimulation with anti-TCR mAb (Fig. 4E).  The proportion of 
CD8+ T cells that produce IFN- or both IFN- and granzyme B were lower in 
Flt3L-treated mice when compared with the control group.  Taken together, these results 
suggest that the activation status of brain-sequestered CD8+ T cells in Flt3L-treated mice 
is diminished when compared with those from untreated mice.   Since sequestration of 
both CD8+ T cells and pRBCs are required for the pathogenesis ECM, we also examined 
the number of pRBCs in the brain of Flt3L-treated mice (Fig. 4F).  The number of 
brain-sequestered pRBCs was strikingly reduced in Flt3L-treated mice, consistent with 
protection from lethal ECM. 
 
Roles of Treg and granulocytes in Flt3L-treated mice  
To investigate the possible role of regulatory CD4+ T cells (Treg) in the differential 
activation of CD8+ T cells in Flt3L-treated mice, we first examined the number of 
Foxp3+Treg cells (Fig. 5A). The proportion of Treg in the spleen of Flt3L-treated mice 
was higher than the proportion in untreated mice, consistent with the previous report (35).  
However, the proportion of Treg did not significantly change after infection with PbA in 
both control and Flt3L-treated mice.  Therefore, Treg did not proliferate preferentially 
Flt3L-treated mice during PbA-infection.  We next examined IFN- production of CD4+ 
T cells, and found that CD4+ T cells from Flt3L-treated and untreated mice produced a 
similar level of IFN- in response to anti-TCR Ab.  Since CD4+ T cells from Flt3L-treated 
and untreated mice contained similar levels of FoxP3+Tregs after infection with PbA, it is 
unlikely that the function of Treg in these two groups of mice is significantly different.   
Therefore, it is unlikely that the differences in CD8+ T cells between Flt3L-treated and 
untreated mice are due to differences in Treg.  
     16 
 
Treatment of mice with Flt3L increased the number of granulocytes and DCs in the spleen 
(Fig. 1B).  The role of granulocytes in malaria pathogenesis was previously evaluated; 
two studies reported that the depletion of granulocytes by antibody-treatment did not 
significantly affect the level of parasitemia, but prevented the development of ECM (7, 
30), while one study reported that granulocyte depletion in the effector phase did not 
affect ECM pathogenesis (3).  Thus, we evaluated the role of granulocytes in the 
inhibition of ECM and parasitemia (Fig. 6).  Depletion of granulocytes with anti-Gr1 
mAb (>99%) prior to the infection did not significantly affect the levels of parasitemia in 
both control and Flt3L-treated mice, and did not alter the inhibitory effect of Flt3L on the 
development of ECM.  Therefore, we concluded that inhibition of ECM by 
Flt3L-treatment was not due to the increase in the number of granulocytes. 
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Discussion 
DCs are critical immune cells in both innate and adaptive immunity. During infection 
with malaria parasites DCs take up Plasmodium-infected RBC and can induce initiation 
of protective immune responses.  To better understand the role of DCs during malaria 
infection, we have taken an approach to expand DCs with Flt3L in vivo prior to infection 
with PbA.  Flt3L was effective in augmenting protective innate immune responses during 
the early phase of PbA infection, and it induced altered activation of CD8+ T cells 
culminating in prevention of ECM.  
 
We employed the hydrodynamic method to induce Flt3L in vivo, and we observed an 
increase in the number of DCs in the spleen.  The proportion of CD8+ DCs was increased 
to more than 50% of all DCs, consistent with the previous report that used adenoviral 
vector expressing recombinant Flt3L (23).  These DCs expressed MHC and 
co-stimulatory molecules at levels similar to controls, and were superior in 
cross-presenting malaria antigens to specific CD8+ T cells, as previously reported (19).  
After infection of Flt3L-treated mice with PbA, a significant reduction of parasitemia 
levels was observed during the initial period of the infection, suggesting that 
Flt3L-treated mice were more protected than untreated mice. We speculate that this initial 
protective response was mainly due to enhancement of innate immunity, since we 
observed a similar reduction in parasitemia levels in Flt3L-treated Rag2-/- mice, which 
lack both T and B cells.  We suspect that the expansion of DCs contribute to reduced 
parasitemia through DC phagocytosis of pRBC.  Granulocytes may be less involved, 
since the parasitemia levels were not significantly increased in mice depleted of 
granulocytes.   This protection, however, was not long-lasting, and parasitemia rose in 
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Flt3L-treated mice until they succumbed to death.   
 
To investigate the mechanisms that lead to the prevention of ECM by Flt3L-treatment, we 
studied the effects of Flt3L-treatment on T cells, since T cells play an instrumental role in 
the pathogenesis of ECM.  We first observed the marked increase in the number of CD8+ 
T cells in the spleen of Flt3L-treated mice after infection with PbA.  Since CD8+ DCs 
preferentially increased in Flt3L-treated mice, we speculate that these DCs 
cross-presented and activated malaria-specific CD8+ T cells. These CD8+ T cells were 
found to produce IFN- in response to PbA antigens at levels equal to or even higher than 
those from untreated mice (Fig. 3B), indicating that priming and IFN- production of 
malaria-specific CD8+ T cells was not impaired in Flt3L-treated mice.  However, 
phenotypic study of the CD8+ T cells in the spleen showed some interesting features.  
First, we unexpectedly found that most CD8+ T cells in PbA-infected mice expressed 
CD11c, an integrin molecule that is often considered a marker of DCs.  CD11c expression 
was also observed on CD8+ T cells after infection with another rodent malaria parasite, 
Plasmodium yoelii (data not shown), and was previously reported in intraepithelial 
lymphocytes (IEL) and recently activated CD8+ T cells in virus-infected mice (4, 13, 18).  
IEL from germ free mice did not express CD11c, and bacterial colonization induced 
CD11c in IEL (13).  However, antigen driven activation of CD8+ T cells alone is not 
sufficient for the induction of CD11c, since we and others failed to induce CD11c on 
CD8+ T cells through stimulation of TCR in vitro (data not shown).  To our knowledge, 
this is the first report of CD11c expression in CD8+ T cells during parasite infection.  
CD11c, forming a heterodimer with 2 integrin (CD18), is involved in the adhesion of 
cells via ligands including ICAM-1, ICAM-2 and VCAM-1 (28).  The absence of CD11c 
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significantly attenuated the severity of experimental autoimmune encephalomyelitis and 
reduced cellular infiltration and demyelination (5).  CD11c may be involved in the 
activation or effector function of CD8+ T cells during PbA-infection via its role in 
strengthening the CD8+ T cell-target cell interaction, thus participating in the 
pathogenesis of ECM.   Alternatively, CD11c may be involved in the preferential 
accumulation of activated CD8+ T cells in the inflamed brain.  However, the expression of 
CD11c on CD8+ T cells is not sufficient for the onset of ECM, because CD8+ T cells in 
PbA-infected BALB/c mice expressed CD11c at levels similar to those in C57BL/6 mice, 
yet PbA-infected BALB/c mice do not develop ECM (data not shown). 
 
The phenotypic characterization of CD8+ T cells from Flt3L-treated mice during 
PbA-infection suggests that their activation status is distinct from CD8+ T cells from 
control mice.  We used CD11c as a general activation marker of CD8+ T cells and 
examined cells that co-express activation-induced molecules with CD11c.  Among 
CD11c+CD8+ T cells from PbA-infected mice, the expression of CD44 and CXCR3 was 
similar between Flt3L-treated and untreated mice, while the expression of CD25, CD137 
and granzyme B was diminished in Flt3L-treated mice. Conventional DCs play critical 
roles for the pathogenesis of ECM (10).  The differential activation of CD8+ T cells in 
Flt3L-treated mice may reflect the difference in the type of DCs that were expanded by 
Flt3L treatment.  In support of this possibility, it was reported that DCs that expanded by 
in vivo administration of Flt3L produced altered cytokine profiles and had tolerogenic 
effects on T cells (23).  DCs are composed of multiple subsets, and the combined action 
of DC stimulation with Flt3L and PbA infection may have resulted in the altered 
phenotype of the activated CD8+ T cells (27).   An alternative possibility is the 
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involvement of other T cells such as helper or regulatory CD4+ T cells that were 
differentially activated in Flt3L-treated mice.  However, Flt3L-treatment resulted in 
similarly increased proportions of regulatory CD4+ T cells both with and without PbA 
infection, consistent with the previous report (35).  In addition, CD4+ T cells from 
Flt3L-treated and untreated mice produced similar levels of IFN- in response to 
anti-TCR mAb.  Thus, regulatory CD4+ T cells are unlikely to be involved in the observed 
phenotypic differences in CD8+ T cells. 
 
Interestingly, the number of T cells recovered from the brain was not significantly 
different between Flt3L-treated and untreated mice after infection with PbA, although 
Flt3L-treated mice did not develop lethal ECM. Expression of CD11c in 
brain-sequestered CD8+ T cells was reduced in Flt3L-treated mice, which might influence 
the strength of the interaction between CD8+ T cells and their target or local tissue. 
Functionally, CD8+ T cells that can produce both IFN- and granzyme B were 
significantly reduced in Flt3L-treated mice, supporting the altered activation status of 
these CD8+ T cells.  Finally, the number of pRBCs in the brain was severely reduced in 
Flt3L-treated mice, which is consistent with the lack of ECM in these mice.  The results 
clearly indicate that accumulation of CD8+ T cells in the brain is not sufficient for the 
sequestration of pRBC in the brain.  We suspect that recruitment of PbA-specific 
activated CD8+ T cells to the brain might condition brain blood vessels for the 
sequestration of pRBC.  In Flt3L-treated mice, CD8+ T cells might not be sufficiently 
activated to achieve this conditioning, while they themselves were able to sequester in the 
brain.   
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ECM is a complex process resulting from the intricate interplay of PbA-infection and the 
host immune response.  We have shown that the development of ECM can be effectively 
prevented by the administration of Flt3L, which stimulates the innate immune system 
including dendritic cells and indirectly alters the activation status of CD8+ T cells after 
infection with PbA.  In addition, the present study indicates that the number of 
brain-sequestered T cells does not directly correlate with the pathogenesis of ECM.  
Further detailed analysis of this system may reveal the critical function of the immune 
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Figure legends 
Figure. 1.  
Expansion of splenic DCs by expression of exogenous Flt3L. 
(A) Mice were inoculated (4 mice) or not (5 mice) with the plasmid pCAGGS-Flt3L 
(5g) by the hydrodynamics method. After 7 days, serum was collected and the level of 
Flt3L was determined by ELISA.  (B) Splenocytes were stained with antibodies and the 
number of DCs (CD11chighCD3-CD19-DX5-), NK cells (TCR-NK1.1+), macrophages 
(CD11c-F4/80highGr1-) and granulocytes (CD11c-Gr1highF4/80-) were determined by 
multiplying the total number of spleen cells with the ratio of each cell type.  The number 
of RBCs (Ter119+CD45-) in peripheral blood was also determined.  *A significant 
difference was observed between untreated and Flt3L-treated mice (p<0.05, 
Mann-Whitney test).  (C) Splenocytes from mice untreated (solid line) or treated (dotted 
line) with pCAGGS-Flt3L were stained with antibodies and flow cytometric analysis of 
MHC class II, CD80, CD86, CD40 (upper panel) and CD4 vs. CD8 (lower panel) on DCs 
are shown.  (D) DCs  (3x104) were prepared from untreated and Flt3L-treated mice, 
pulsed with and without pRBC lysate  (1 mg/ml) and were cocultured with splenic CD4+ 
or CD8+ T cells (1x105) from PbA-infected mice.  After 48 hrs, the levels of IFN- in the 
supernatant were determined by ELISA.  The experiments were repeated twice and the 
representative data are shown. 
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Figure. 2.  
Flt3L-treatment enhanced innate immunity against malaria infection, and prevented the 
development of lethal ECM by mechanisms independent of the reduction of parasitemia. 
(A) Mice were untreated (blue line, 6 mice) or inoculated with Flt3L-expressing plasmid 
(green line, 5 mice) or empty vector (red line, 5 mice) on day-7, and were infected with 
pRBC on day0. Survival was monitored daily (left). The shaded area (day6-10) indicates 
dates that ECM symptoms appear in this disease model in general. *A significant 
difference was observed between untreated or empty vector-treated vs 
pCAGGS-Flt3L-treated mice (p<0.05, logrank test). Parasitemia was monitored every 
2-3 days in surviving mice and the mean ± SD in each group was indicated (right).  * A 
significant difference was observed between untreated or empty vector-treated vs 
Flt3L-treated mice (p<0.05, Mann-Whitney test). 
(B) 6 days after infection with PbA, the integrity of the blood-brain barrier was evaluated 
by injection of Evans blue solution.  
(C) Rag2-/- mice were untreated (blue line, 6 mice) or Flt3L-treated (green line, 5 mice) 
and infected with pRBC 7 days later.  Parasitemia level was monitored every 2-3 days and 
the mean ± SD in each group was shown. * A significant difference was observed 
between untreated and Flt3L-treated mice (p<0.05, Mann-Whitney test). 
(D) Untreated or Flt3L-treated C57BL/6 mice were infected with PbA-GFP. Five days 
after infection, spleen cells were analyzed using flow cytometry. Numbers in the upper 
right corner indicate percentage of GFP+ cells within CD11chigh DCs (upper panel).  The 
expression of Ly6C within GFP+CD11c- cells is shown (lower panel). 
(E) Mice (3 mice) were infected with the indicated number of pRBC. Survival was 
monitored daily (left). * p<0.05, logrank test.  The levels of parasitemia 5 days after 
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infection are expressed as mean ± SD (right).  
(F) Sera were collected from untreated or Flt3L-treated mice (3 mice/group) five days 
after PbA-infection, and were subjected to CBA assay. The mean ± SD in each group was 
shown. (G) Mice (3 mice/Flt3L and pCAGGS groups, 5 mice/untreated group) were 
infected with PbA and were untreated (blue line) or inoculated with Flt3L-expressing 
plasmid (green line) or empty vector (red line) on day 4. The levels of parasitemia were 
monitored and the mean ± SD in each group was determined. The experiments (A-D, F) 
were repeated twice and the representative data are shown. 
 
 
Figure 3  
The number of CD8+ T cells was markedly increased in Flt3L-treated mice after infection 
with PbA. 
(A) Mice were untreated or Flt3L-treated and were infected or not infected with PbA for 5 
days.  Spleen cells and PBL were stained for CD4, CD8 and TCR, and the number of 
CD4+ and CD8+ T cells was calculated. * p<0.05, Mann-Whitney test. (B) CD8+ T cells 
were cultured in triplicate wells in the presence of DCs pulsed with nothing (open bar), 
pRBC lysate (filed bar) or RBC lysate (gray bar) for 48 hrs, and the levels of IFN- were 
determined by ELISA. The experiments were repeated twice and the representative data 
are shown. 
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Figure 4 
The activation phenotype of CD8+ T cells from Flt3L-treated mice after PbA-infection 
was distinct from that of untreated mice.   
(A) B6 mice were uninfected (solid line) or infected (dotted line) with PbA.  Five days 
later, spleen cells were stained for CD11c, TCR, CD8 and CD4, and the expression of 
CD11c on CD8+ and CD4+ T cells was examined.  (B, C) Mice were untreated or treated 
with Flt3L, uninfected or infected with PbA, and splenocytes were stained with mAbs 5 
days after infection.  The dot plots demonstrate the expression of CD11c, CD44, CXCR3 
(B) and CD25 (C, upper) on CD8+ T cells. The number in each quadrant represents the 
proportion of cells within the region. The histograms demonstrate expression of CD25, 
CD137 and granzyme B on splenic CD11c+CD8+ T cells from untreated (green) and 
Flt3L-treated (red) mice 5 days after PbA-infection, or from untreated mice without 
infection (black).  
(D, left) Brain-sequestered cells were isolated from uninfected and infected mice (3 
mice/group) and their total cell number was quantified. Cells were stained for CD45, 
Ter119, CD4, CD8 and TCR, and the numbers of CD8+ and CD4+ T cells 
(CD45+Ter119-TCR+) were calculated and expressed as mean ± SD.  (D, right) The 
expression of CD44 and CD11c on brain-sequestered CD8+ T cells from untreated (green) 
and Flt3L-treated (red) B6 mice after 6 days of PbA-infection.  The black line represents 
control unstained brain-sequestered CD8+ T cells.  N.S.= not significant, Mann-Whitney 
test between Ctrl and Flt3L groups.  (E) Brain-sequestered CD8+ T cells were stimulated 
with anti-TCR mAb, and the expression of IFN- and granzyme B was determined using 
intracellular staining.  * p<0.05, Mann-Whitney test.  (F) Mice (3 mice/group) were 
treated and untreated with Flt3L and were infected with PbA. After 6 days, 
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brain-sequestered pRBCs were counted.  * p<0.05, Mann-Whitney test. The experiments 
were repeated twice and the representative data are shown. 
 
 
Figure 5  
Treg are unlikely to be involved in inhibition of CD8+ T cell activation in Flt3L-treated 
mice after PbA infection. 
(A) Untreated (3 mice/group) and Flt3L-treated (4 mice/group) mice were uninfected or 
infected with PbA. After 5 days, splenocytes were stained for CD4, CD25 and Foxp3.  
The ratio of Tregs (CD4+CD25+Foxp3+) within CD4+ T cells was expressed as mean ± 
SD in each group. * p<0.05, Mann-Whitney test. 
(B) Five days after infection, CD4+ splenic T cells were stimulated with plate-bound anti- 
TCR mAb, and their IFN- production was determined by ELISA in quadruplicate assay. 
The experiments were repeated twice and the representative data are shown. 
 
 
Figure 6.  
The role of granulocytes on Flt3L-mediated effects in PbA infection.  
Mice were untreated or treated with Flt3L 7 days prior to infection and received anti-Gr1 
mAb (50 g) i.p. 2 days prior to infection.  The levels of parasitemia 5 days after infection 
are expressed as mean ± SD (left). N.S.= not significant, Mann-Whitney test. Survival of 
infected mice was monitored daily (right). * p<0.05, logrank test. The experiments were 



































































































































CD8 T cells 
-      + -      + 
Ctrl DC Flt3L DC 
-      + -      + 
Ctrl DC Flt3L DC 















Flt3L Ctrl Ctrl 




















0 5 10 15 20


































0 5 10 15
Ctrl
Flt3L










































































































































































































































































green:Ctrl  red:Flt3L black: Uninfected 
CD137 CD25 





















Ctrl Ctrl Flt3L Ctrl Ctrl Flt3L 






































































































































0 5 10 15
Ctrl
Ctrl + anti-Gr1 
Flt3L
Flt3L + anti-Gr1


































































































Days after infection 
A
B C
Supplemetal Figure 1: 
The correlation between the number of DCs and anti-malaria effect in mice treated with Flt3L. 
(A) A different doses (0-5 μg/mouse) of the plasmid encoding Flt3L were injected into C57BL/6
 mice (3 mice/group) by the hydrodynamics method. After seven days, spleens were collected, 
and analyzed using flow cytometry. The number of DCs was calculated by multiplying the total 
spleen cell number with the ratio of CD11c+MHC class II+ cells. (B, C) The indicated doses of 
the plasmid were introduced into C57BL/6 mice by hydrodynamics method. After seven days, 
the mice were infected with pRBCs (2X105 cells) by i.p. inoculation. The levels of parasitemia (%) 
were determined five days after infection (B), and survival of the mice was monitored (C).
Supplemetal Figure 2:
Inhibition of the parasitemia by inoculation with Flt3L-induced DCs. 
Flt3L-DCs were purified from C57BL/6 mice that were inoculated with Flt3L-plasmid (5μg/mouse) 
by hydrodynamics method. Seven days later, splenic DCs were purified by cell sorting using 
FACSAria as described in Materials and Methods. BM-DCs were obtained using standard method
 by culturing bone marrow cells in media containing GM-CSF (1). C57BL/6 mice were inoculated 
with (Flt3L-DCs, BM-DCs, 3 mice/group) and without (Ctrl, 5 mice) these DCs (2X106 cells) i.p., 
and were infected with PbA by i.p. inoculation with pRBCs (1X106 cells). Five days after infection, 
the levels of parasitemia were determined.
Reference:
1. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. Schuler. 1999. 
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse
 bone marrow. J Immunol Methods 223:77-92.
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